ChapterPDF Available

Nutritional Support After Bariatric Surgery

Authors:

Abstract

Obesity is a disease with a significant morbidity and mortality. About 3.4 million deaths related to obesity have been estimated worldwide in 2010, and its prevalence rose by 27.5% among adults between 1980 and 2013. Because of the far superior results of the surgical treatment compared to the medical therapy for obesity, the American Society for Metabolic and Bariatric Surgery has issued a grade A recommendation for bariatric surgery in patients with a body mass index (BMI) ≥40 kg/m² or for those with BMI ≥35 kg/m² and comorbidity unresponsive to previous medical treatment.
Nutritional Support after Bariatric Surgery
Sebastio Perrini
Bariatric surgery provides substantial and sustained effects on weight loss and ameliorates obesity-
attributable comorbidities in the majority of bariatric patients, although risks of complication,
reoperation, and death exist (1). While a patient’s surgeon monitors closely for postoperative
surgical complications, the primary care provider or endocrinologist is often the provider to identify
and manage postoperative medical and nutritional complications. This chapter reviews these
potential nutritional complications with attention to screening, and therapeutic approach.
Early and Late Nutritional Management
Most bariatric procedures include the reduction of the volume of the stomach and/or the
creation of a small gastric pouch. Therefore, the ingestion of solid foods in the first days after
surgery is impossible and a gradual change of food consistency in the first post-operative
weeks is preferred in order to avoid or minimise regurgitation and vomiting, which can
threaten the integrity and safety of the recent surgical procedure, and result in severe vitamin
B1 (thiamine) deficiency (2). After bariatric surgery, a low-sugar clear liquid meal programme is
usually initiated within 24 h, and patients are then informed to gradually and progressively change
the food consistency, moving from clear liquids to soft or creamy foods and then to solid chewable
items over a period of 2-4 weeks (2,3). The aim of dietary counselling should be the fitting of
patients’ eating behaviour to the surgical procedure and the general qualitative aspects of a healthy
nutrientdense diet. In detail, patients with gastric restriction should be counselled to eat three
small meals during the day and chew small bites of food thoroughly befo re swallowing,
without drinking beverages at the same time (more than 30 min apart) (2,3). Regular physical
activity is considered a critical factor for weight maintenance and should therefore be encouraged
after bariatric surgery. Patients should be advised to carry out moderate aerobic physical activity,
i.e., a minimum of 150 min/week (with a goal of 300 min/week) as well as strength training 23
times/week (2-3).
Protein Supplementation
Protein intake is generally reduced following bariatric surgery and then adequate protein intake is
prominent to counteract the loss of lean body mass in any situation when a rapid weight loss occurs
(4). Dietary counselling should address the problem of protein intake, particularly in the first
months after surgery. Current guidelines suggest a minimal protein intake of 60 g/day and up to 1.5
g/kg ideal body weight per day, but higher amounts of protein intake (up to 2.1 g/kg ideal body
weight per day) may be required in individual cases (2-6). The use of liquid protein supplements
(30 g/day) can facilitate adequate protein intake in the first period after surgery. Bariatric
procedures involving a certain degree of malabsorption can cause protein malnutrition. The
incidence of protein malnutrition depends on the degree of the malabsorption as well as on the
dietary habits and the protein requirements of the patients. A 13% incidence has been reported after
distal Roux-en Y gastric bypass (RYGB) with a Roux limb ≥ 150 cm, whereas an incidence of
protein malnutrition ranging from 3 to 18% has been reported after biliopancreatic diversion (3).
Prevention of protein malnutrition involves regular rating of protein intake, fostering the ingestion
of protein-rich foods (>60 g/day) divided into several meals and the use of modular protein
supplements (2,3). In case of severe non-responsive protein malnutrition parenteral nutrition is
recommended, and surgical revision with lengthening of the common channel to decrease
malabsorption should be considered if a patient remains dependent on parenteral nutrition or has
recurrent episodes of protein depletion (2-4) .
Micronutrient Deficiencies
Given the dietary changes, rerouting of nutrient flow, and gut anatomy/physiology alterations that
occur after bariatric surgery, patients who undergo these procedures are at risk for micronutrient
deficiencies. Some of these deficiencies can result in severe consequences, such as neuropathy,
heart failure, and encephalopathy. Therefore, it is extremely important that patients understand the
need for lifelong supplementation. Patients who have malabsorptive procedures, such as Roux-en-Y
Gastric Bypass (RYGB) or BilioPancreatic Diversion with Duodenal Switch (BPD/DS), are at
highest risk for micronutrient deficiencies and require a more extensive preoperative nutritional
evaluation and postoperative monitoring and supplementation. But even with restrictive procedures,
decreased oral intake and poor tolerance to certain food groups may also increase the risk for
micronutrient deficiencies (2-5).
Tables 1-3 represent recommendations that have been adapted from the American Society for
Metabolic and Bariatric Surgery (ASMBS) Integrated Health Nutrition Guidelines (6), Clinical
Practice Guidelines from the combined American Association of Clinical Endocrinologists
(AACE), The Obesity Society (TOS), and ASMBS (7), and The Endocrine Society Clinical Practice
Guidelines (8). These recommendations for adults reflect general guidelines, and patients with
specific diseases may require further evaluation and closer monitoring. For example, in
malabsorptive bariatric surgical procedures the resulting nutritional anemias beyond that an
appropriate iron repletion might also require other micronutrient deficiencies in vitamin B12, folate,
protein, copper, selenium and zinc, and these should be evaluated.
Preexisting micronutrient deficiencies would be corrected prior to surgery in order to avoid
clinically symptomatic or severe disease. For example, suboptimal levels of 25-hydroxyvitamin D
are particularly common and may require supplementation prior to surgery.
Is universally accepted that post-bariatric supplementation (Table 1) is an important component of
postoperative care. For example, vitamin B12 deficiency is common after RYGB without adequate
supplementation, and oral doses of 350 mcg/day have been shown to maintain normal plasma B12
levels. Other suggested micronutrient doses are either based on expert opinion or are similar to the
recommended dietary allowance (RDA) (6-8).
Table 1. Recommended postoperative supplementation of vitamins and minerals
Micronutrient
Supplementation
Within a multivitamin with minerals product
Thiamine
12 mg/day
Vitamin B12 (cobalamin)
Oral or sublingual: 350-500 mcg/day
Intranasal: 1000 mcg/week*
Intramuscular: 1000 mcg/month
Folate (folic acid)
400-800 mcg/day
Women of childbearing age: 800-1000 mcg/day
Iron
18 mg/day elemental iron
RYGB, SG, BPD/DS or menstruating women: 45-60 mg/day
Take separately from calcium supplements
Vitamin D
D3 3000 IU/day
Vitamin A
LAGB: vitamin A 5000 IU/day
RYGB or SG: vitamin A 5,000-10,000 IU/day
BPD/DS: vitamin A 10,000 IU/day
Vitamin E
15 mg/day
Vitamin K
LAGB, SG or RYGB: 90-120 mcg/day
BPD/DS: 300 mcg/day
Zinc
SG or LAGB: 8-11 mg/day
RYGB: 8-22 mg/day
BPD/DS: 16-22 mg/day
Copper
SG or LAGB: 1 mg/day
RYGB or BPD/DS: 2 mg/day
As separate supplementation
Calcium
LAGB, SG, RYGB: calcium 1200-1500 mg/day (diet + supplements)
BPD/DS: calcium 1800-2400 mg/day (diet + supplements)
(as calcium citrate, in divided doses)
Most micronutrients are provided in multivitamins, and chewable multivitamins are recommended
postoperatively. Multivitamins for the general population can be used, provided that attention is
paid to the product’s micronutrient contents. The ASMBS recommends one general multivitamin
tablet daily for patients who have had Laparoscopic Adjustable Gastric Banding (LAGB), or 2
general multivitamin tablets daily for those undergoing Sleeve Gastrectomy (SG), RYGB or
BPD/DS. As an alternative to general multivitamins, bariatric surgery-specific, high-potency
multivitamins are available and often contain the recommended doses of micronutrients in one
tablet daily (6).
Multivitamins do not contain the recommended doses of calcium, as calcium can impede the
absorption of other micronutrients. Therefore, separate calcium supplementation is usually required.
Calcium citrate is the preferred form of supplemental calcium, as it is better absorbed than calcium
carbonate in the state of impaired gastric acid production. A patient’s dietary calcium intake should
be considered when determining the dose of a calcium supplement, as the recommended intakes are
generally total daily intakes (diet plus supplements) (6). Iron absorption may be enhanced by co-
administration of vitamin C (500-1000 mg) to create an acidic environment or when taken with
meat. If inadequate absorption or intolerance occurs, parenteral iron replacement may be necessary.
A suggested schedule for postoperative biochemical monitoring is listed in Table 2. Patients who
develop micronutrient deficiencies may need more frequent monitoring.
Examinations should be performed after RYGB or BPD/DS. All of these could be suggested for
patients submitted to restrictive surgery where frank deficiencies are less common.
Some surgeons perform additional early biochemical evaluation 3 months postoperatively, and the
AACE/TOS/ASMBS Clinical Practice Guidelines suggest evaluation earlier than 6 months for
some micronutrients (7).
Table 2. Schedule for postoperative micronutrient monitoring
6 months
12 months
18 months
24 months
Vitamin B12
X
X
X
X
Folate
X
X
X
X
Iron, ferritin
X
X
X
X
25-hydroxyvitamin D
X
X
X
X
Calcium
X
X
X
X
Intact PTH
X
X
X
X
24-hour urinary calcium
X
X
X
Thiamine
Optional
Optional
Optional
Optional
Vitamin A
Optional
Zinc
Optional
Optional
Optional
Copper
Optional
Oral repletion is often sufficient for correcting micronutrient deficiencies, although parenteral
therapy may be required in severe disease. After a repletion course, biochemical testing should be
performed and a maintenance dose should be established. Micronutrient deficiencies may co-exist;
for example, malabsorptive procedures may result in deficiencies of the fat-soluble vitamins A, E
and K (6-8).
Table 3. Repletion recommendations for micronutrient deficiencies
Micronutrient
Repletion recommendation
Thiamine
Oral: 100 mg 2-3 times daily
IM: 250 mg daily for 3-5 days or 100-250 mg monthly
IV: 200 mg 2-3 times daily to 500 mg 1-2 times daily for 3-5 days, followed
by 250 mg/day for 3-5 days
Severe disease: administer thiamine prior to dextrose-containing solutions
Vitamin
B12(cobalamin)
Oral: 1000 mcg/day
IM: 1000 mcg/month to 1000-3000 mcg/6-12 months
Folate (folic acid)
1000 mcg/day orally
Iron
150-200 mg elemental iron/day, up to 300 mg 2-3 times daily
Calcium may impair iron absorption
Consider co-administration of vitamin C to enhance absorption
Consider IV iron infusions for severe/refractory iron deficiency
Vitamin D
D3 6000 IU/day or D2 50,000 IU 1-3 times per week, or more if needed to
achieve and maintain 25-hydroxyvitamin D >30 ng/mL
Calcium
Increase dose and titrate to normalize PTH ± 24-hr urinary calcium level
Vitamin A
10,000-25,000 IU/day orally until clinical improvement (1-2 weeks)
With corneal changes: 50,000-100,000 IU IM x 3 days, then 50,000 IU/day
IM for 2 weeks
Vitamin E
Optimal therapeutic dose not clearly defined, consider 100-400 IU/day
Vitamin K
Acute malabsorption: 10 mg parentally
Chronic malabsorption: 1-2 mg/day orally or 1-2 mg/week parentally
Zinc
There is insufficient evidence to make a dose-related recommendation
Copper
Mild-moderate deficiency: oral copper gluconate or sulfate 3-8 mg/day
Severe deficiency: 2-4 mg/day of intravenous copper x 6 days
IM, intramuscular; IV, intravenous
Dumping Syndrome
Dumping syndrome was believed to be typical of gastric bypass (7075% of patients in the first
year after surgery) (7) , but it has been described also after sleeve gastrectomy (40% of patients 6
months after surgery) (15) . Early dumping syndrome typically occurs within 1 hour of eating and is
characterized by both gastrointestinal (nausea, abdominal fullness, diarrhea) and vasomotor
symptoms (fainting, sleepiness, weakness, diaphoresis, palpitations, and desire to lie down) (10).
Dumping syndrome symptoms can appear as early as 6 weeks after surgery and has been reported to
affect up to 20% according to large survey studies and up to 40% in smaller prospective studies of
individuals who have undergone both restrictive and malabsorptive procedures (11-14). The
pathophysiology of dumping syndrome is not completely understood but is thought to be due to
both a rapid delivery of nutrients to the small intestine causing an osmotic shift of intravascular
fluid to the intestinal lumen as well as an increased release of gastrointestinal hormones that disrupt
motility and hemodynamic status (15). There is debate in the literature on whether dumping
syndrome is an adaptive consequence of bariatric surgery that helps restrict food intake and aids
weight loss versus an adverse consequence that reduces quality of life and does not contribute to
weight loss (11).
The diagnosis of dumping syndrome should be made after the exclusion of more serious entities
such as intestinal fistulas, adhesions, ischemia, herniation, obstipation and gallstone disease which
may have shared clinical features (15). There are validated questionnaires as well as provocation
tests that have been used to confirm dumping syndrome in research settings. Oral glucose challenge
with an increase in heart rate and hematocrit (indicating hemoconcentration) is one such approach
(10).
The first line treatment for dumping syndrome is to modify the diet so as to avoid foods that worsen
symptoms (oftentimes calorie-dense foods with high fat/refined sugar content and low in fiber),
eating small volume meals, not eating and drinking at the same time, eating slowly, chewing well,
and avoiding alcohol. Indeed, patients often implement these changes on their own and, over time,
symptom severity improves or resolves in many (if not most) patients. In addition, lying down for
30 minutes after eating to slow gastric emptying and mitigate symptoms of hypovolemia may be
helpful if symptoms occur (15). There are several small interventional studies and case reports that
support the use of dietary supplements (e.g., pectin, guar gum) that increase food viscosity and
reduced symptoms of dumping syndrome, however low palatability and potential choking hazard
and bowel obstruction are downsides to their use (15). Somatostatin analogs have also been tested
in small studies, although this class of drugs are expensive, involve subcutaneous or intramuscular
injections, and have gastrointestinal side effects (15). Enteral tube feedings or bariatric surgery
reversal have been reported to improve symptoms when all else fails (15).
Conclusions
The postoperative management of the bariatric surgery patient requires a special knowledge and
skills of the clinicians in order to deliver appropriate and effective care to the post-bariatric patient.
Thus, an interdisciplinary team, including the surgeon, dietitian, and endocrinologist and/or primary
care provider should provide a follow-up program as an integral part of the clinical pathway at
centres delivering bariatric surgery. This follow-up program should be include the management of
chronic metabolic conditions and the prevention and treatment of postoperative medical and
nutritional complications to optimize the long-term benefits of bariatric surgery.
References
1) Su-Hsin Chang, Carolyn R.T. Stoll, Jihyun Song, J. Esteban Varela, Christopher J. Eagon,
Graham A. Colditz. Bariatric surgery: an updated systematic review and meta-analysis,
20032012. JAMA Surg. 2014 Mar 1; 149(3): 275287.
2) Busetto L, Dicker D, Azran C, Batterham RL, Farpour-Lambert N, Fried M, et al. Obesity
Management Task Force of the European Association for the Study of Obesity Released
"Practical Recommendations for the Post-Bariatric Surgery Medical Management". Obes
Surg. 2018 Jul;28(7):2117-2121.
3) Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML,
Spitz AF, et al. American Association of Clinical Endocrinologists, The Obesity Society,
and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical
practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric
surgery patient. Obesity (Silver Spring). 2009;17 Suppl 1:S1-70.
4) Faintuch J, Matsuda M, Cruz ME, Silva MM, Teivelis MP, Garrido AB Jr, Gama-Rodrigues
JJ: Severe protein calorie malnutrition after bariatric procedures. Obes Surg 2004; 14: 175
181.
5) Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, et al. Clinical
practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of
the bariatric surgery patient-2013 update: cosponsored by American Association of Clinical
Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric
Surgery. Obesity (Silver Spring) 2013; 21(suppl 1):S1S27.
6) Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for
Metabolic and Bariatric Surgery integrated health nutritional guidelines for the surgical
weight loss patient 2016 update: micronutrients. Surg Obes Relat Dis. 2017; 13:727-741.
7) Mechanick JI1, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, et al.
Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical
support of the bariatric surgery patient-2013 update: Cosponsored by American Association
of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic &
Bariatric Surgery. Endocr Pract. 2013; 19:337-372.
8) Heber D, Greenway FL, Kaplan LM, Livingston E, Salvador J, Still C. Endocrine and
nutritional management of the post-bariatric surgery patient: an Endocrine Society clinical
practice guideline. J Clin Endocrinol Metab. 2010; 95:4823-4843.
9) Papamargaritis D, Koukoulis G, Sioka E, Zachari E, Bargiota A, Zacharoulis D, Tzovaras G:
Dumping symptoms and incidence of hypoglycaemia after provocation test at 6 and 12
months after laparoscopic sleeve gastrectomy. Obes Surg 2012; 22: 16001606.
10) Laurenius A, Olbers T, Naslund I, Karlsson J. Dumping syndrome following gastric bypass:
validation of the dumping symptom rating scale. Obes Surg. 2013; 23:740-755.
11) Banerjee A, Ding Y, Mikami DJ, Needleman BJ. The role of dumping syndrome in weight
loss after gastric bypass surgery. Surgical endoscopy. 2013; 27:1573-1578.
12) Nielsen JB, Pedersen AM, Gribsholt SB, Svensson E, Richelsen B. Prevalence, severity, and
predictors of symptoms of dumping and hypoglycemia after Roux-en-Y gastric bypass. Surg
Obes Relat Dis. 2016; 12:1562-1568.
13) Papamargaritis D, Koukoulis G, Sioka E, et al. Dumping symptoms and incidence of
hypoglycaemia after provocation test at 6 and 12 months after laparoscopic sleeve
gastrectomy. Obes Surg. 2012; 22:1600-1606.
14) Tzovaras G, Papamargaritis D, Sioka E, et al. Symptoms suggestive of dumping syndrome
after provocation in patients after laparoscopic sleeve gastrectomy. Obes Surg. 2012; 22:23-
28.
15) van Beek AP, Emous M, Laville M, Tack J. Dumping syndrome after esophageal, gastric or
bariatric surgery: pathophysiology, diagnosis, and management. Obes Rev. 2017; 18:68-85.
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
The worldwide obesity epidemic continues unabated, adversely impacting upon global health and economies. People with severe obesity suffer the greatest adverse health consequences with reduced life expectancy. Currently, bariatric surgery is the most effective treatment for people with severe obesity, resulting in marked sustained weight loss, improved obesity-associated comorbidities and reduced mortality. Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), the most common bariatric procedures undertaken globally, engender weight loss and metabolic improvements by mechanisms other than restriction and malabsorption. It is now clear that a plethora of gastrointestinal (GI) tract-derived signals plays a critical role in energy and glucose regulation. SG and RYGB, which alter GI anatomy and nutrient flow, impact upon these GI signals ultimately leading to weight loss and metabolic improvements. However, whilst highly effective overall, at individual level, post-operative outcomes are highly variable, with a proportion of patients experiencing poor long-term weight loss outcome and gaining little health benefit. RYGB and SG are markedly different anatomically and thus differentially impact upon GI signalling and bodyweight regulation. Here, we review the mechanisms proposed to cause weight loss following RYGB and SG. We highlight similarities and differences between these two procedures with a focus on gut hormones, bile acids and gut microbiota. A greater understanding of these procedure-related mechanisms will allow surgical procedure choice to be tailored to the individual to maximise post-surgery health outcomes and will facilitate the discovery of non-surgical treatments for people with obesity.
Article
Full-text available
Bariatric patients may face specific clinical problems after surgery, and multidisciplinary long-term follow-up is usually provided in specialized centers. However, physicians, obstetricians, dieticians, nurses, clinical pharmacists, midwives, and physical therapists not specifically trained in bariatric medicine may encounter post-bariatric patients with specific problems in their professional activity. This creates a growing need for dissemination of first level knowledge in the management of bariatric patients. Therefore, the Obesity Management Task Force (OMTF) of the European Association for the Study of Obesity (EASO) decided to produce and disseminate a document containing practical recommendations for the management of post-bariatric patients. The list of practical recommendations included in the EASO/OMTF document is reported in this brief communication.
Article
Full-text available
Background and aim: Several bariatric surgery worldwide surveys have been previously published to illustrate the evolution of bariatric surgery in the last decades. The aim of this survey is to report an updated overview of all bariatric procedures performed in 2014.For the first time, a special section on endoluminal techniques was added. Methods: The 2014 International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) survey form evaluating the number and the type of surgical and endoluminal bariatric procedures was emailed to all IFSO societies. Trend analyses from 2011 to 2014 were also performed. Results: There were 56/60 (93.3%) responders. The total number of bariatric/metabolic procedures performed in 2014 consisted of 579,517 (97.6%) surgical operations and 14,725 (2.4%) endoluminal procedures. The most commonly performed procedure in the world was sleeve gastrectomy (SG) that reached 45.9%, followed by Roux-en-Y gastric bypass (RYGB) (39.6%), and adjustable gastric banding (AGB) (7.4%). The annual percentage changes from 2013 revealed the increase of SG and decrease of RYGB in all the IFSO regions (USA/Canada, Europe, and Asia/Pacific) with the exception of Latin/South America, where SG decreased and RYGB represented the most frequent procedure. Conclusions: There was a further increase in the total number of bariatric/metabolic procedures in 2014 and SG is currently the most frequent surgical procedure in the world. This is the first survey that describes the endoluminal procedures, but the accuracy of provided data should be hopefully improved in the next future. We encourage the creation of further national registries and their continuous updates taking into account all new bariatric procedures including the endoscopic procedures that will obtain increasing importance in the near future.
Article
Full-text available
Obesity has been a problem since medieval times, but only in the latter 20 years it has been recognized as a worldwide epidemic. Treating obesity is challenging and difficult, but surgery has led to an increased success and novel insights on the pathophysiology of obesity. Several surgical techniques have been developed during the last 50 years and the advent of laparoscopic surgery has increased its safety, efficacy and demand from the population. Nowadays, the ever increasing and successful use of novel techniques have been responsible for several changes in the established treatment paradigms.
Article
Full-text available
Background: Dumping syndrome, a common complication of esophageal, gastric or bariatric surgery, includes early and late dumping symptoms. Early dumping occurs within 1 h after eating, when rapid emptying of food into the small intestine triggers rapid fluid shifts into the intestinal lumen and release of gastrointestinal hormones, resulting in gastrointestinal and vasomotor symptoms. Late dumping occurs 1-3 h after carbohydrate ingestion, caused by an incretin-driven hyperinsulinemic response resulting in hypoglycemia. Clinical recommendations are needed for the diagnosis and management of dumping syndrome. Methods: A systematic literature review was performed through February 2016. Evidence-based medicine was used to develop diagnostic and management strategies for dumping syndrome. Results: Dumping syndrome should be suspected based on concurrent presentation of multiple suggestive symptoms after upper abdominal surgery. Suspected dumping syndrome can be confirmed using symptom-based questionnaires, glycemia measurements and oral glucose tolerance tests. First-line management of dumping syndrome involves dietary modification, as well as acarbose treatment for persistent hypoglycemia. If these approaches are unsuccessful, somatostatin analogues should be considered in patients with dumping syndrome and impaired quality of life. Surgical re-intervention or continuous enteral feeding may be necessary for treatment-refractory dumping syndrome, but outcomes are variable. Conclusions: Implementation of these diagnostic and treatment recommendations may improve dumping syndrome management.
Article
Full-text available
Endoscopic bariatric therapy may be a useful alternative to pharmacological treatment for obesity, and it provides greater efficacy with lower risks than do conventional surgical procedures. Among the various endoscopic treatments for obesity, the intragastric balloon is associated with significant efficacy in body weight reduction and relief of comorbid disease symptoms. Anatomically, this treatment is based on gastric space-occupying effects that increase the feeling of satiety and may also affect gut neuroendocrine signaling. The simplicity of the intragastric balloon procedure may account for its widespread role in obesity treatment and its applicability to various degrees of obesity. However, advances in device properties and procedural techniques are still needed in order to improve its safety and cost-effectiveness. Furthermore, verification of the physiological outcomes of intragastric balloon treatment and the clinical predictive factors for treatment responses should be considered. In this article, we discuss the types, efficacy, safety, and future directions of intragastric balloon treatment.
Article
Obesity constitutes a major global health threat. Despite the success of bariatric surgery in delivering sustainable weight loss and improvement in obesity-related morbidity, effective non-surgical treatments are urgently needed, necessitating an increased understanding of body weight regulation. Neuroimaging studies undertaken in people with healthy weight, overweight, obesity and following bariatric surgery have contributed to identifying the neurophysiological changes seen in obesity and are increasing our understanding of the mechanisms driving the favourable eating behaviour changes and sustained weight loss engendered by bariatric surgery. These studies have revealed a key interplay between peripheral metabolic signals, homeostatic and hedonic brain regions and genetics. Findings from brain functional magnetic resonance imaging (fMRI) studies have consistently associated obesity with an increased motivational drive to eat, increased reward responses to food cues and impaired food-related self-control processes. Interestingly, new data link these obesity-associated changes with structural and connectivity changes within the central nervous system. Moreover, emerging data suggest that bariatric surgery leads to neuroplastic recovery. A greater understanding of the interactions between peripheral signals of energy balance, the neural substrates that regulate eating behaviour, the environment and genetics will be key for the development of novel therapeutic strategies for obesity. This review provides an overview of our current understanding of the pathoaetiology of obesity with a focus upon the role that fMRI studies have played in enhancing our understanding of central regulation of eating behaviour and energy homeostasis.
Article
The pathogenesis of human obesity is the result of dysregulation of the reciprocal relationship between food intake and energy expenditure (EE), which influences daily energy balance and ultimately leads to weight gain. According to principles of energy homeostasis, a relatively lower EE in a setting of energy balance may lead to weight gain; however, results from different study groups are contradictory and indicate a complex interaction between EE and food intake which may differentially influence weight change in humans. Recently, studies evaluating the adaptive response of one component to perturbations of the other component of energy balance have revealed both the existence of differing metabolic phenotypes (“spendthrift” and “thrifty”) resulting from overeating or underfeeding, as well as energy-sensing mechanisms linking EE to food intake, which might explain the propensity of an individual to weight gain. The purpose of this review is to debate the role that human EE plays on body weight regulation and to discuss the physiologic mechanisms linking EE and food intake. An increased understanding of the complex interplay between human metabolism and food consumption may provide insight into pathophysiologic mechanisms underlying weight gain, which may eventually lead to prevention and better treatment of human obesity.
Article
Bariatric surgery in obese individuals leads to rapid and lasting remission of type 2 diabetes (T2D). This phenomenon occurs independently of weight loss possibly via a combination of factors. The incretin hormone GLP-1 has so far been recognised as a critical factor. However, recent data have indicated that elevation in another gut hormone, peptide tyrosine tyrosine (PYY), may drive the beneficial effects of surgery. Here we discuss recent findings on PYY-mediated control of glucose homeostasis and its role in diabetes, in the context of what is known for GLP-1. Identification of factors that increase the expression of PYY following bariatric surgery and elucidation of its role in diabetes reversal may have clinical relevance as a nonsurgical therapy for T2D.
Article
Background: Roux-en-Y gastric bypass (RYGB) results in pronounced weight loss in morbidly obese patients but may also cause adverse effects like early dumping and hypoglycemia. Prevalence data on these complications and their potential predictors are sparse. Objective: To assess the prevalence and possible predictors of early dumping and hypoglycemia in a population-based cohort of RYGB patients. Setting: University Hospital, Denmark. Design: A questionnaire survey was performed in the Central Denmark Region including RYGB-operated patients (years 2006-2011, n = 2238) and a nonoperated comparison cohort (n = 89). The Dumping Rating Scale and the Edinburgh Hypoglycemia Scoring System, together with demographic and clinical characteristics, were used, and possible predictors were examined by logistic regression. Results: The response rate was 64% (1429/2238). In total, 9.4% (134/1429) and 6.6% (95/1429) experienced moderate or severe symptoms of early dumping and hypoglycemia, respectively, which were significantly higher than in the comparison cohort. Because 3.4% (95% CI: 2.5-4.4) of the RYGB group experienced both early dumping and hypoglycemia, the total prevalence of 1 or both conditions was 12.6 (95% CI 10.9-14.4). Possible predictors for both conditions were body mass index (BMI)<25 kg/m(2) (odds ratio [OR] 1.70 (95% CI: 0.98-2.95) and OR 1.60 (95% CI: .83-3.06), respectively) compared with patients with BMI 25-30 kg/m(2). Younger age seemed to increase the risk of both conditions (<35 yr: OR 1.75 (95% CI: 1.11-2.75) and OR .59 (95% CI: .93-2.72), respectively) compared with patients>45 years. Conclusion: Symptoms of early dumping and hypoglycemia were rather common with a prevalence of 1 or both conditions of 12.6% after RYGB. Predictors included younger age and a lower BMI.